Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles

Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe(3)O(4) nanoparticles radiolabeled with (68)Ga, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Karageorgou, Maria-Argyro, Stamopoulos, Dimosthenis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105398/
https://www.ncbi.nlm.nih.gov/pubmed/33963211
http://dx.doi.org/10.1038/s41598-021-89117-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105398/
https://www.ncbi.nlm.nih.gov/pubmed/33963211
http://dx.doi.org/10.1038/s41598-021-89117-3

Ejemplares similares